

January 31, 2001

Luitpold Pharmaceuticals, Inc.  
Attention: Mary Jane Helenek  
One Luitpold Drive  
Shirley, NY 11967

Dear Madam:

This is in reference to your abbreviated new drug application dated October 23, 1998, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act (Act), for Leucovorin Calcium Injection USP, (Preservative-Free), 50 mg (base)/vial, (10 mg/mL).

Reference is also made to your amendments dated October 9, November 14, and December 8, 2000; and January 8, 2001.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the application is approved. The drug product, Leucovorin Calcium Injection USP, (Preservative-Free), 50 mg (base)/vial, can be expected to have the same therapeutic effect as that of the listed drug product upon which the Agency relied as the basis of safety and effectiveness.

Under Section 506A of the Act, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.

Post-marketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

We request that you submit, in duplicate, any proposed advertising or promotional copy that you intend to use in your initial advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final print. Submit both copies together with a copy of the proposed or final printed labeling to the Division of Drug Marketing, Advertising,

and Communications (HFD-40). Please do not use Form FD-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) for this initial submission.

We call your attention to 21 CFR 314.81(b)(3) which requires that materials for any subsequent advertising or promotional campaign be submitted to our Division of Drug Marketing, Advertising, and Communications (HFD-40) with a completed Form FD-2253 at the time of their initial use.

Sincerely yours,

Gary Buehler  
Acting Director  
Office of Generic Drugs  
Center for Drug Evaluation and Research

cc: ANDA 40-338  
Division File  
Field Copy  
HFD-610/R.West  
HFD-210/B.Poole  
HFD-330  
HFD-205/F.O.I.

Endorsements:

HFD-629/G.Kang/11/28/00  
HFD-629/P.Schwartz/11/28/00  
HFD-617/E.Hu/11/29/00  
HFD-600/P.DeLeo/11/29/00  
HFD-640/L.Ensor for A.High/11/29/00  
HFD-613/J.Grace for T.Watkins/11/29/00  
HFD-613/J.Grace/  
\\CDS008\WP51F99\FIRMSAM\LUITPOLD\LTRS&REV\40338.AP2.doc

F/T by

APPROVAL